CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
using liquid biopsy to guide the post-surgical and post-adjuvant clinical management in 140 microsatellite stable Stage-III and T4N0 Stage-II colon...
Phase 2
Barcelona, Spain and 10 other locations
(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...
Phase 3
Barcelona, Spain and 212 other locations
The purpose of this study is to measure tumor response to treatment with ompenaclid (RGX-202) in patients with previously treated RAS mutant advanced...
Phase 2
Barcelona, Spain and 27 other locations
and pembrolizumab) given together for the treatment of colorectal cancer that:is metastatic (spread to other parts of the body);has the cond...
Phase 2
Barcelona, Catalunya [cataluña], Spain and 108 other locations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitr...
Phase 1
Barcelona, Spain and 32 other locations
to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer...
Phase 1, Phase 2
Barcelona, Barcelona [Barcelona], Spain and 83 other locations
in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended do...
Phase 1
Barcelona, Catalunya, Spain and 12 other locations
A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm teste...
Phase 1
Barcelona, Catalunya, Spain and 17 other locations
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET...
Phase 1, Phase 2
Barcelona, Barcelona [Barcelona], Spain and 25 other locations
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor...
Phase 1
Barcelona, Spain and 63 other locations
Clinical trials
Research sites
Resources
Legal